The FDA suggests that difficulty swallowing tablets and capsules can be addressed by controlling various physical attributes of the tablet or capsule. However, these recommendations fail to tackle the problem directly as patients still have to deal with dosage forms that are negatively impacting compliance and their health.
With a wealth of convincing data available, the widespread nature of this problem is undeniable. This situation needs addressing, and by doing so presents a rare opportunity for innovative companies to alleviate patient problems while generating new streams of revenue.
To read the article which has been published in Pharmaceutical Executive, pages 46-47, volume 35, no. 10 please check the digital version of the October issue of Pharmaceutical Executive